MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$1,611K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Proceeds from issuance of common...
Deferred revenue
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Total operating expenses
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue from collaboration agreements
6,641
-18,779
-
24,931
research and development
-
24,606
-
-
General and administrative
-
9,331
-
-
Total operating expenses
33,064
-83,071
-
117,008
Non-operating income
2,788
-4,913
-
7,569
Net loss
-23,635
-25,129
-20,486
-32,166
Stock-based compensation expense
3,036
2,671
4,007
4,593
Impairment loss on right-of-use asset
-
-
10,733
-
Impairment of long-lived assets
-
-
-
10,733
Depreciation and amortization
-
-
1,959
-
Depreciation and amortization expense
292
-1,127
-
460
Reduction in carrying amount of right-of-use asset
1,454
1,441
1,429
1,688
Net accretion of discounts on marketable securities
186
1,089
863
515
Other
12
30
21
30
Accounts receivable
-1,549
482
-4,141
4,341
Prepaid expenses and other current and long-term assets
1,659
-122
2,258
572
Accounts payable
348
-85
-472
-885
Accrued expenses and other current liabilities
3,993
-3,522
2,069
-2,015
Operating lease liability
-1,588
-1,536
-1,480
-1,461
Deferred revenue
14,810
-2,769
-8,681
-6,756
Net cash used in operating activities
-1,574
-29,944
-22,145
-31,207
Proceeds from maturities of marketable securities
56,051
57,029
52,349
51,180
Purchases of marketable securities
70,829
40,812
133,071
46,683
Purchases of property and equipment, net
37
64
11
411
Net cash provided by investing activities
-14,815
16,153
-80,733
4,086
Proceeds from issuance of common stock-Underwritten Offering
-
-
116,870
-
Proceeds from issuance of common stock-At The Market
-
-
-
7,526
Proceeds from issuance of common stock-At The Market Equity Program
-
-
9,341
-
Proceeds from issuance of common stock-Stock Purchase Agreement
-
-
-
0
Proceeds from issuance of common stock-Betta Pharma Stock Purchase Agreement
-
-
0
-
Proceeds from exercise of stock options
176
605
0
107
Proceeds from issuance of common stock from at-the-market equity offering
33,548
-
-
-
Proceeds from exercise of warrants
1
1
-
-
Payments for repurchase of common stock for tax withholding
0
200
14
24
Other
0
56
1
164
Net cash provided by (used in) financing activities
33,725
462
118,672
7,773
Net change in cash, cash equivalents and restricted cash
17,336
-13,329
15,794
-19,348
Cash, cash equivalents and restricted cash at beginning of period
64,717
78,046
62,252
58,942
Cash, cash equivalents and restricted cash at end of period
82,053
-
-
-
Cash, cash equivalents and restricted cash at end of period
82,053
64,717
78,046
62,252
Less restricted cash
3,443
-
-
-
Cash and cash equivalents at end of the period
78,610
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock from...
$33,548K
Proceeds from exercise of
stock options
$176K
Proceeds from exercise of
warrants
$1K
Net cash provided by
(used in) financing...
$33,725K
(73415.22%↑ Y/Y)
Net change in cash,
cash equivalents and...
$17,336K
(-23.49%↓ Y/Y)
Canceled cashflow
$16,389K
Proceeds from maturities
of marketable...
$56,051K
(-51.49%↓ Y/Y)
Deferred revenue
$14,810K
(535.72%↑ Y/Y)
Accrued expenses and
other current...
$3,993K
(165.43%↑ Y/Y)
Stock-based compensation
expense
$3,036K
(-71.08%↓ Y/Y)
Accounts receivable
-$1,549K
(-71.92%↓ Y/Y)
Reduction in carrying
amount of right-of-use...
$1,454K
(-56.17%↓ Y/Y)
Accounts payable
$348K
(-60.85%↓ Y/Y)
Depreciation and
amortization expense
$292K
(-72.74%↓ Y/Y)
Other
$12K
(-75.00%↓ Y/Y)
Net cash provided by
investing activities
-$14,815K
(-121.77%↓ Y/Y)
Net cash used in
operating activities
-$1,574K
(96.53%↑ Y/Y)
Canceled cashflow
$56,051K
Canceled cashflow
$25,494K
Revenue from
collaboration agreements
$6,641K
Non-operating income
$2,788K
Purchases of marketable
securities
$70,829K
(49.68%↑ Y/Y)
Net loss
-$23,635K
(54.85%↑ Y/Y)
Purchases of property and
equipment, net
$37K
(-80.00%↓ Y/Y)
Canceled cashflow
$9,429K
Prepaid expenses and
other current and...
$1,659K
(141.75%↑ Y/Y)
Operating lease liability
-$1,588K
(43.95%↑ Y/Y)
Net accretion of
discounts on marketable...
$186K
(-86.36%↓ Y/Y)
Total operating
expenses
$33,064K
Buy us a coffee
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)